Department of Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4497-e4508. doi: 10.1210/clinem/dgab465.
CONTEXT: Understanding phenotypic connection between type II diabetes (T2D) mellitus and amyotrophic lateral sclerosis (ALS) can offer valuable sight into shared disease etiology and have important implication in drug repositioning and therapeutic intervention. OBJECTIVE: This work aims to disentangle the nature of the inverse relationship between T2D mellitus and ALS. METHODS: Depending on summary statistics of T2D (n = 898 130) and ALS (n = 80 610), we estimated the genetic correlation between them and prioritized pleiotropic genes through a multiple-tissue expression quantitative trait loci-weighted integrative analysis and the conjunction conditional false discovery rate (ccFDR) method. We implemented mendelian randomization (MR) analyses to evaluate the causal relationship between the 2 diseases. A mediation analysis was performed to assess the mediating role of T2D in the pathway from T2D-related glycemic/anthropometric traits to ALS. RESULTS: We found supportive evidence of a common genetic foundation between T2D and ALS (rg = -0.223, P = .004) and identified 8 pleiotropic genes (ccFDR < 0.10). The MR analyses confirmed that T2D exhibited a neuroprotective effect on ALS, leading to an approximately 5% (95% CI, 0% ~ 9.6%, P = .038) reduction in disease risk. In contrast, no substantial evidence was observed that supported the causal influence of ALS on T2D. The mediation analysis revealed T2D can also serve as an active mediator for several glycemic/anthropometric traits, including high-density lipoprotein cholesterol, overweight, body mass index, obesity class 1, and obesity class 2, with the mediation effect estimated to be 0.024, -0.022, -0.041, -0.016, and -0.012, respectively. CONCLUSION: We provide new evidence supporting the observed inverse link between T2D and ALS, and revealed that a shared genetic component and causal association commonly drove such a relationship. We also demonstrate the mediating role of T2D standing in the pathway from T2D-related glycemic/anthropometric traits to ALS.
背景:理解 2 型糖尿病(T2D)和肌萎缩侧索硬化症(ALS)之间的表型联系,可以深入了解两种疾病的共同发病机制,并为药物重新定位和治疗干预提供重要依据。
目的:本研究旨在阐明 T2D 和 ALS 之间负相关关系的本质。
方法:根据 T2D(n=898130)和 ALS(n=80610)的汇总统计数据,我们估计了它们之间的遗传相关性,并通过多组织表达定量性状基因座加权综合分析和联合条件错误发现率(ccFDR)方法优先考虑了多效性基因。我们进行了孟德尔随机化(MR)分析,以评估这两种疾病之间的因果关系。进行中介分析以评估 T2D 在 T2D 相关的血糖/人体测量特征到 ALS 的途径中的中介作用。
结果:我们发现 T2D 和 ALS 之间存在共同的遗传基础的有力证据(rg=-0.223,P=0.004),并确定了 8 个多效性基因(ccFDR<0.10)。MR 分析证实 T2D 对 ALS 具有神经保护作用,使疾病风险降低约 5%(95%CI,0%~9.6%,P=0.038)。相反,没有发现实质性证据支持 ALS 对 T2D 的因果影响。中介分析表明,T2D 也可以作为几种血糖/人体测量特征(包括高密度脂蛋白胆固醇、超重、体重指数、肥胖 1 级和肥胖 2 级)的主动中介,估计的中介效应分别为 0.024、-0.022、-0.041、-0.016 和-0.012。
结论:我们提供了新的证据支持观察到的 T2D 和 ALS 之间的反向关联,并揭示了共同的遗传成分和因果关联共同驱动了这种关系。我们还证明了 T2D 在 T2D 相关的血糖/人体测量特征到 ALS 的途径中的中介作用。
J Clin Endocrinol Metab. 2021-10-21
Front Endocrinol (Lausanne). 2021
Sci Rep. 2022-2-15
Ann Neurol. 2019-3-13
Front Nutr. 2025-7-30
J Neural Transm (Vienna). 2025-6-14
Trends Mol Med. 2023-12
Nat Rev Neurol. 2023-9
Front Neurosci. 2023-4-24
Nat Rev Genet. 2023-9
Foods. 2021-12-17